文献速递角膜与眼表疾病

口服米替福星作为难治性棘阿米巴角膜炎的挽救治疗

Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis.
PubMed 文献 · Am J Ophthalmol · 2020-10-10

这项回顾性多中心病例系列纳入15例对治疗无反应的棘阿米巴角膜炎患者,在2011至2017年间接受口服米替福星作为辅助或挽救治疗。所有患者最终无病,11/15保留数指或更好视力;11/15出现炎症加重,其中10例经激素改善。口服米替福星总体耐受良好,常见副作用为轻度胃肠道症状。

要点

  • 口服米替福星可作为难治性棘阿米巴角膜炎的辅助挽救治疗。
  • 治疗中常见激素反应性炎症加重,临床应有所准备。
  • 多数患者耐受良好,常见轻度胃肠道症状。

核心结论

  • 口服米替福星是难治性棘阿米巴角膜炎患者总体耐受良好的辅助治疗。
  • 临床医生应准备应对治疗过程中常见的激素反应性炎症反应。

研究设计与样本

  • 描述性、回顾性多中心病例系列。
  • 纳入15例对治疗无反应的棘阿米巴角膜炎患者,在2011至2017年间接受辅助全身米替福星治疗。

主要发现

  • 15例中11例保留数指或更好视力,所有患者在末次随访时被认为无病。
  • 15例中11例使用米替福星后炎症加重,其中10例经激素改善。
  • 6例接受了多疗程米替福星。
  • 多数患者口服米替福星耐受良好,最常见全身副作用为轻度胃肠道症状。

关键数值与推荐

  • 所有患者在开始米替福星前均使用双胍类和/或二脒类或唑类药物但疾病未缓解。

临床怎么用

  • 对常规治疗无反应的棘阿米巴角膜炎可考虑加用口服米替福星作为挽救治疗。
  • 治疗期间需监测炎症加重,并及时使用激素处理激素反应性炎症。

局限性

  • 回顾性、描述性病例系列,样本量小(15例),无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy. DESIGN: Descriptive, retrospective multicenter case series. METHODS: We reviewed 15 patients with AK unresponsive to therapy who were subsequently given adjuvant systemic miltefosine between 2011 and 2017. The main outcome measures were resolution of infection, final visual acuity, tolerance of miltefosine, and clinical course of disease. RESULTS: All patients were treated with biguanides and/or diamidines or azoles without resolution of disease before starting miltefosine. Eleven of 15 patients retained count fingers or better vision, and all were considered disease free at last follow-up. Eleven of 15 patients had worsening inflammation with miltefosine, with 10 of them improving with steroids. Six patients received multiple courses of miltefosine. Most tolerated oral miltefosine well, with mild gastrointestinal symptoms as the most common systemic side effect. CONCLUSIONS: Oral miltefosine is a generally well-tolerated treatment adjuvant in patients with refractory AK. The clinician should be prepared for a steroid-responsive inflammatory response frequently encountered during the treatment course.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Thulasi P, Saeed HN, Rapuano CJ, et al. Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. Am J Ophthalmol. 2020. PMID: 33045218. doi:10.1016/j.ajo.2020.09.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。